Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Hepatitis C, Chronic 1Hepatitis C 1Fibrosis 1Diabetes Mellitus 1Cardiovascular Diseases 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 39atezolizumab 26durvalumab 24Nivolumab 21lenvatinib 20tremelimumab 16Specimen Handling 16Magnetic Resonance Spectroscopy 13sintilimab 11pembrolizumab 11Ipilimumab 10tislelizumab 7X-Rays 7Sorafenib 7Immunoglobulin G 7regorafenib 6Disulfides 6Cyclophosphamide 6cabozantinib 5Radiotherapy 5Radiosurgery 5Blood Specimen Collection 5Radiation 4Oxaliplatin 4Immunotherapy 4Fluorouracil 4Ethiodized Oil 4Biopsy 4fludarabine 3donafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × sofosbuvir-velpatasvir drug combination × 90 days × Clear all
NCT03520660 2026-06-03

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

National Institutes of Health Clinical Center (CC)

Phase 4 Active not recruiting
121 enrolled
Gastrointestinal

Cardiovascular Diseases, Diabetes Mellitus, Fibrosis, Hepatitis C, Carcinoma, Hepatocellular, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡